PRESS RELEASE

Annual General Meeting 2021 of Heidelberg Pharma Approves All Proposed Resolutions

Ladenburg, Germany, 18 May 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98,40% to 99,99%) during the virtual Annual General Meeting today.

- Resolution on the formal approval of the actions of the members of the Executive Management Board and the Supervisory Board for the fiscal year 2020

- Resolution on the appointment of the auditor of the annual financial statements and the consolidated financial statements for the 2020/2021 fiscal year

- Resolution to revoke the Conditional Capital II, as well as to amend the Articles of Association accordingly

- Resolution on one further amendment to the Articles of Association regarding a change in the law

- Resolution concerning the remuneration of the members of the Executive Management and Supervisory Board

Presence (including postal voting) at the Annual General Meeting 2021 corresponded to 81,57% of the current share capital.

Heidelberg Pharma made use of the option provided by the German legislature in view of the coronavirus pandemic to conduct ordinary annual general meetings also in 2021 without the physical presence of shareholders or their proxies. Via a password-protected web service, registered shareholders can, among other things, follow the entire Annual General Meeting live via video and audio, exercise their voting rights and submit questions.

Dr. Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer of Heidelberg Pharma AG, commented: "Today, we successfully held our second Annual General Meeting in virtual format. We are pleased that the shareholders or their proxies took advantage of this opportunity and submitted their questions electronically. On behalf of the Management Board, I would like to thank the shareholders of Heidelberg Pharma AG for their confidence in our Company and their long-standing support."

Please find more information about the Annual General Meeting including the voting results here: https://heidelberg-pharma.com/en/AGM.

Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma.

Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.